A-BIO PHARMA PTE. LTD.

Business Description

A-BIO PHARMA PTE. LTD. is registered as a business entity on 17 August 2001 (23.6 years ago) structured as a Private Company Limited By Shares (Local Company) with 4 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 200105467N. The business official address is located at 137 Telok Ayer Street #05-05, Singapore 68602 in the primary industry of 21022: Manufacture Of Other Biological Products And Preparations For Human Use using Singapore Dollars - SGD as its default trading currency. The business legal name has undergone change(s) and is previously known as SEMBCORP BIOMEDICAL PTE LTD, SEMBIO PHARMA PTE LTD. The business annual account filing date falls on 31 July and is currently operational with the status of 'Live Company'. The business paid up share capital is SGD 0.1, with preference share capital of SGD 12,500,000, and other share capital at SGD 0.

In the past 365 days, A-BIO PHARMA PTE. LTD. has received a total of Login to view reported payment review(s). 12 were rated Good and Login to view were rated Poor. The latest review was made on 2023-07-27 and it was reported "Good". The aggregated good payment amount is equivalent to USD 11,964, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The appointment of ERNST & YOUNG LLP as auditor indicates that the business is medium to large sized as it is required to meet additional regulatory requirements either due to reported revenue or assets exceeding SGD 10 million or has more than 50 employees in the previous two fiscal years.

A-BIO PHARMA PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023